Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06620913

Acronym

CarTo-CV2

Enrollment

232

Registered

2024-10-01

Start date

2024-05-01

Completion date

2026-05-01

Last updated

2024-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CV2 Autoimmunity

Keywords

Paraneoplastic neurological disorders, lung cancer, CV2 autoimmunity, immune tolerance breakdown

Brief summary

Paraneoplastic neurological syndromes are rare syndromes caused by the remote effects of cancer. They have an immune-mediated pathogenesis, yet the underlying mechanisms are not fully elucidated. CV2/Collapsin response-mediator protein 5 (CRMP5)-IgG paraneoplastic neurological syndrome is characterized by heterogeneous clinical presentations, affecting both central and peripheral nervous system, and the most frequently associate tumor is small cell lung carcinoma. Central nervous system involvement along with CSF and neuroimaging findings have not been fully described in the literature in CV2/CRMP5 patients. Unraveling the complexities of CV2/CRMP5 paraneoplastic neurological syndrome is critical to improve diagnosis, treatment, and patients' care. Our intention is to perform a comprehensive analysis of the clinical characteristics and instrumental investigations of a large cohort of CV2/CRMP5 patients.

Interventions

OTHERDescription of clinical, immunological and tumor features of patients harboring CV2 Abs

This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient with paraneoplastic neurological syndromes * Patient with CV2 antibody in sera and/or CSF

Exclusion criteria

* Patient with no data * Patient without neurological disorder * Patient without CV2 antibody in sera/CSF

Design outcomes

Primary

Measure	Time frame	Description
Modified Rankin Scale (mRs)	At baseline, 3, 6, 12, 18 month	Application of modified rankin scale

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026